AbbVie (ABBV) Non-Current Deferred Tax Liability (2012 - 2026)

AbbVie (ABBV) has reported Non-Current Deferred Tax Liability for 15 consecutive years, with $2.3 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Non-Current Deferred Tax Liability fell 10.85% year-over-year to $2.3 billion in Q2 2026; TTM through Jun 2026 was $2.3 billion, a 10.85% decrease from a year earlier, with the FY2025 full-year figure at $2.4 billion, down 20.07% from the prior year.
• Non-Current Deferred Tax Liability was $2.3 billion for Q2 2026 at AbbVie, down from $2.3 billion in the prior quarter.
• Over five years, Non-Current Deferred Tax Liability peaked at $4.7 billion in Q4 2022 and troughed at $2.0 billion in Q3 2022.
• A 5-year average of $2.6 billion and a median of $2.5 billion in 2025 frame the typical range for Non-Current Deferred Tax Liability.
• Across the five-year window, Non-Current Deferred Tax Liability plunged 45.25% in 2022 and soared 34.49% in 2024, its largest moves.
• Over 5 years, Non-Current Deferred Tax Liability stood at $4.7 billion in 2022, then sank by 43.53% to $2.7 billion in 2023, then increased by 12.58% to $3.0 billion in 2024, then dropped by 20.07% to $2.4 billion in 2025, then slipped by 4.69% to $2.3 billion in 2026.
• The last three Non-Current Deferred Tax Liability figures came in at $2.3 billion (Q2 2026), $2.3 billion (Q1 2026), and $2.4 billion (Q4 2025), per Business Quant data.